Breakthroughs in cell-penetrating monoclonal antibody therapies
Peer-Reviewed Publication
Updates every hour. Last Updated: 1-May-2025 06:08 ET (1-May-2025 10:08 GMT/UTC)
A critical study sheds light on the growing global burden of esophageal cancer, outlining its significant impact and the imperative to identify the driving factors behind its increasing prevalence.
Identifying novel therapeutic strategies and making fundamental discoveries related to small cell lung cancer. Creating environmental and sustainable solutions for lithium-ion battery technology. Improving the safety and efficacy of gene editing and understanding the mechanisms of DNA repair to potentially cure diseases. Discovering the most distant and massive galaxies that have reshaped our understanding of early Universe star formation and supermassive black holes. Pioneering geochemical fingerprinting technology to optimize energy production processes. These are the breakthroughs by Texas’ rising stars in research being honored with the 2025 Edith and Peter O’Donnell Awards by TAMEST (Texas Academy of Medicine, Engineering, Science & Technology).
A novel study from Korea uncovers the process of synthesis and pivotal role of the transfer RNA-derived fragment, 5′-tRH-GlyGCC in cancer progression. By interacting with splicing factors, it regulates gene expression, alternative splicing, and messenger RNA processing. This research highlights its role as a cancer biomarker and explores its potential as a therapeutic target. With promising results from antisense oligonucleotide therapies, this discovery could pave the way for groundbreaking advancements in cancer treatment.
Large-scale protein and gene profiling have massively expanded the landscape of cancer-associated proteins and gene mutations, but it has been difficult to discern whether they play an active role in the disease or are innocent bystanders. In this study, researchers at Baylor College of Medicine revealed a powerful and unbiased machine learning-based approach called FunMap for assessing the role of cancer-associated mutations and understudied proteins, with broad implications for advancing cancer biology and informing therapeutic strategies.
A team led by researchers at the Technical University of Munich (TUM) has, for the first time, grown tumor organoids – three-dimensional miniature tumors in the laboratory – that mimic the different structures and characteristics of pancreatic cancer. The scientists investigated how the various tumor organoids react to established and novel treatments. This opens the door to the development of effective new therapies.